Clinical trial
Effectiveness of Cannabidiol vs. Narcotics for Post Operative Pain Control in Elective Knee Arthroscopic Surgery
Name
USF006030
Description
This is a prospective, randomized, nonblinded trial to evaluate the effectiveness of Cannabidiol (CBD) oil on post-operative pain control compared to opioid medications after a knee arthroscopy.
Trial arms
Trial start
2023-10-15
Estimated PCD
2025-07-15
Trial end
2025-12-30
Status
Not yet recruiting
Phase
Early phase I
Treatment
Cannabidiol Oil
Subjects will self administer CBD sublingually
Arms:
Cannabidiol Oil 100 mg/day, Cannabidiol Oil 200 mg/day
Size
100
Primary endpoint
Post-operative pain control
30 days post-operatively
Eligibility criteria
Inclusion Criteria:
* Age 18 or older
* requiring knee arthroscopy for soft tissue injury, acute or chronic knee injury
* able to complete surveys and follow-up visits
Exclusion Criteria:
* younger than 18 years of age
* history of knee dislocation, fracture, previous surgery, coexisting extremity pathology, \*pregnancy.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2023-09-13
1 organization
1 product
1 indication
Product
CannabidiolIndication
Postoperative Pain